The Proteosys-backed pharmaceutical company, formed through a merger last year, is also set to raise $26m from a concurrent private placement to Johnson & Johnson.
Minerva Neurosciences, a US-based developer of treatments for central nervous system (CNS) diseases, has filed for an initial public offering that could raise up to $69m.
Minerva was formed in 2013 from the merger of Cyrenaic Pharmaceuticals and Sonkei Pharmaceuticals, and although details of Cyrenaic and Sonkei’s past funding are not publicly available, ProteoSys, a Germany-based commercial medical research institution, holds a 5.7% stake in Minerva, and is set to acquire additional shares in a concurrent private placement, though details…
